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Macrophage migration inhibitory factor (MIF) is an important cytokine for which an increasing number of
functions is being described in the pathogenesis of inflammation and cancer. Nevertheless, the availability
of potent and druglike MIF inhibitors that are well-characterized in relevant disease models remains
limited. Development of highly potent and selective small-molecule MIF inhibitors and validation of their
use in relevant disease models will advance drug discovery. In this review, we provide an overview of recent
advances in the identification of MIF as a pharmacological target in the pathogenesis of inflammatory
diseases and cancer. We also give an overview of the current developments in the discovery and design of
small-molecule MIF inhibitors and define future aims in this field.Introduction
Despite its discovery over 50 years ago in 1966 [1,2], the functions
of the cytokine macrophage migration inhibitory factor (MIF)
have still not been fully elucidated. Initially, MIF was identified
as a T-cell-derived mediator that inhibits random movement of
macrophages. Its activity was found to correlate with delayed-type
hypersensitivity reactions, a prominent feature of several chronic
diseases in humans [2]. In addition, MIF is released at sites of
infection, causing macrophages to concentrate and carry out
antigen processing and phagocytosis [3]. Today, MIF is recognized
as a crucial player in innate immune responses and has a role in
multiple diseases [4,5]. Therefore, the development of small-mol-
ecule MIF inhibitors that inferfere with its functions is quickly
gaining importance.
The human MIF gene was cloned and expressed for the first time
in 1989 [6]. MIF is a relatively small protein that consists of 114
amino acids and has a molecular mass of 12 345 Da. Structural
analysis of MIF revealed its striking similarities to bacterialPlease cite this article in press as: Kok, T. et al. Small-molecule inhibitors of macrophage migrati
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genome indicated that D-dopachrome tautomerase (D-DT) is an-
other gene with marked homology to MIF. Owing to this similari-
ty, D-DT is also referred to as MIF2 and an overlapping functional
spectrum for MIF and D-DT has been suggested [7]. This should be
considered in the evaluation of MIF cytokine activities and in the
development of small-molecule MIF modulators.
MIF, a member of the tautomerase superfamily [8], is found
across various organisms including bacteria, mice, plants, proto-
zoa, helminths, molluscs, arthropods and fish [9–11]. These tau-
tomerase superfamily members have similar enzyme activity
involving an amino-acid-terminal proline that acts as a general
base in keto-enol tautomerisation reactions of a-keto-carboxy-
lates. In addition to its cytokine activity, MIF harbors keto-enol
tautomerase and low-level dehalogenase activity, providing a
functional link to other members of the tautomerase superfamily
[10]. MIF is a homotrimeric protein in which three monomers
associate to form a symmetrical trimer (Fig. 1a). Each MIF trimer
has three tautomerase active sites at the interfaces of the monomer
subunits. Characteristic for this family, MIF has an N-terminalon inhibitory factor (MIF) as an emerging class of therapeutics for immune disorders, Drug
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